MoonLake Immunotherapeuti Valuation
| MLTX Stock | USD 39.67 0.91 2.24% |
At this time, the firm appears to be undervalued. MoonLake Immunotherapeuti secures a last-minute Real Value of $48.04 per share. The latest price of the firm is $39.67. Our model forecasts the value of MoonLake Immunotherapeuti from analyzing the firm fundamentals such as Current Valuation of 2.09 B, shares owned by insiders of 15.47 %, and Return On Equity of -0.25 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MoonLake Immunotherapeuti's valuation include:
Undervalued
Today
Please note that MoonLake Immunotherapeuti's price fluctuation is very steady at this time. Calculation of the real value of MoonLake Immunotherapeuti is based on 3 months time horizon. Increasing MoonLake Immunotherapeuti's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since MoonLake Immunotherapeuti is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MoonLake Stock. However, MoonLake Immunotherapeuti's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.67 | Real 48.04 | Target 76.33 | Hype 40.21 | Naive 43.08 |
The intrinsic value of MoonLake Immunotherapeuti's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MoonLake Immunotherapeuti's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MoonLake Immunotherapeutics helps investors to forecast how MoonLake stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MoonLake Immunotherapeuti more accurately as focusing exclusively on MoonLake Immunotherapeuti's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use MoonLake Immunotherapeuti's intrinsic value based on its ongoing forecasts of MoonLake Immunotherapeuti's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against MoonLake Immunotherapeuti's closest peers.
MoonLake Immunotherapeuti Cash |
|
MoonLake Valuation Trend
Analysing the historical paterns of MoonLake Immunotherapeuti's enterprise value and its market capitalization is a good way to estimate and gauge the value of MoonLake Immunotherapeutics over time and is usually enough for investors to make rational market timing decisions.
MoonLake Immunotherapeuti Total Value Analysis
MoonLake Immunotherapeutics is now anticipated to have valuation of 2.09 B with market capitalization of 2.57 B, debt of 2.83 M, and cash on hands of 92.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MoonLake Immunotherapeuti fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.09 B | 2.57 B | 2.83 M | 92.71 M |
MoonLake Immunotherapeuti Asset Utilization
One of the ways to look at asset utilization of MoonLake is to check how much profit was generated for every dollar of assets it reports. MoonLake Immunotherapeutics secures a negative usage of assets of -0.18 %, losing $0.001781 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of MoonLake Immunotherapeutics shows how discouraging it operates for each dollar spent on its assets.MoonLake Immunotherapeuti Ownership Allocation
The majority of MoonLake Immunotherapeuti outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MoonLake Immunotherapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MoonLake Immunotherapeuti. Please pay attention to any change in the institutional holdings of MoonLake Immunotherapeuti as this could imply that something significant has changed or is about to change at the company.MoonLake Immunotherapeuti Profitability Analysis
Net Loss for the year was (121.24 B) with profit before overhead, payroll, taxes, and interest of 0.About MoonLake Immunotherapeuti Valuation
Our relative valuation model uses a comparative analysis of MoonLake Immunotherapeuti. We calculate exposure to MoonLake Immunotherapeuti's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MoonLake Immunotherapeuti's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -11.8 K | -12.4 K |
MoonLake Immunotherapeuti Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 62.9 M |
MoonLake Immunotherapeuti Current Valuation Indicators
Valuation refers to the process of determining the present value of MoonLake Immunotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value MoonLake we look at many different elements of the entity such as MoonLake's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MoonLake Immunotherapeuti, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MoonLake Immunotherapeuti's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MoonLake Immunotherapeuti's worth.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.